- Home
- RARE vs IAC Comparison
RARE vs IAC Comparison
Compare RARE & IAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | IAC |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2014 | 1992 |
Fundamental Metrics
Financial Performance| Metric | RARE | IAC |
|---|---|---|
| Price | $22.74 | $39.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | ★ $73.11 | $45.91 |
| AVG Volume (30 Days) | ★ 4.0M | 895.4K |
| Earning Date | 02-12-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $630,598,000.00 | ★ $3,653,760,000.00 |
| Revenue This Year | $19.68 | N/A |
| Revenue Next Year | $19.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.63 | ★ 23.49 |
| 52 Week Low | $18.41 | $29.56 |
| 52 Week High | $46.50 | $50.49 |
Technical Indicators
Market Signals| Indicator | RARE | IAC |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 55.17 |
| Support Level | $22.40 | $39.37 |
| Resistance Level | $24.65 | $40.65 |
| Average True Range (ATR) | 1.53 | 0.94 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 64.17 | 53.25 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About IAC IAC Inc.
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.